Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omicron Variant Vaccines vs mRNA-1273 Booster Study
NCT05249829Phase 3Completed
- Sponsor
- Moderna Inc
- Start
- Feb 2022
- Primary completion
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of elasomeran + imelasomeran and mRNA-1273.529 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Moderna Inc. Primary endpoints: Geometric Mean Concentration of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 85, Geometric Mean Concentration of mRNA-1273.214 and mRNA-1273 Against the B.1.1.529 Strain at Day 85 and 4 more. Started Feb 2022; status: completed.
02
Drugs
elasomeran + imelasomeranmRNA-1273.529
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05249829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05249829.